Dr. Hamilton on ONT-380/T-DM1 in HER2+ Breast Cancer
Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase Ib study examining ONT-380 in combination with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer, and what potential the combination has in the neoadjuvant setting.
Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase Ib study examining ONT-380 in combination with trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer, and what potential the combination has in the neoadjuvant setting.
The study examined the efficacy and safety of patients with metastatic disease in the second-line setting and included patients with treated and untreated brain metastases, Hamilton explains. Previous data suggest that ONT-380 is able to cross the blood-brain barrier. Results showed that there was a 47% response rate in patients and the median progression-free survival was 8 months. In patients who were CNS evaluable, over one-third had responses in the brain.
Due to the encouraging findings, Hamilton predicts that this regimen could be studied in the neoadjuvant setting.
